Background Bacteria-induced respiratory infection has been long considered to be the major cause of acute exacerbation of chronic obstructive pulmonary disease （AECOPD）.Therefore,a clear picture about the distributi...Background Bacteria-induced respiratory infection has been long considered to be the major cause of acute exacerbation of chronic obstructive pulmonary disease （AECOPD）.Therefore,a clear picture about the distribution and drug-resistance of pathogenic bacteria in the lower airways should be helpful for treatment of the disease.So far,data on this topic among Chinese are lacking.Methods A surveillance study was performed in consecutive patients with AECOPD at five areas in China between October 2006 and April 2008.The sputum from these patients was cultured and isolated for bacteria.Agar dilution method was used to determine the minimal inhibitory concentrations （MICs） of levofloxacin and other 15 antibiotics against these strains.Results Three hundred and fifty-nine pathogenic bacterial strains were isolated among 884 patients with AECOPD.The predominant bacteria were Pseudomonas aeruginosa （21.7%）,Klebsiella pneumoniae （12.3%）,Haemophilus influenzae （14.2%） and Streptococcus pneumoniae （11.7%）,followed by Haemophilus parainfluenzae （9.5%）,Acinetobacter baumannii （7.8%）,Moraxella catarrhalis （6.4%） and Escherichia coli （3.6%）.The majority of bacterial pathogens isolated in this study were susceptible to fluoroquinolones,ceftazidime,cefepime and imipenem.Conclusions Gram-negative bacilli are the leading pathogens in patients with AECOPD in China.Haemophilus parainfluenzae may be one of the most important pathogens in AECOPD.This study provides evidence for local surveillance of AECOPD pathogens and appropriate choice of antimicrobials in China.展开更多
Background The socio-economic burden of acute exacerbation of chronic obstructive pulmonary disease （AECOPD） in Beijing is not fully understood. The study investigated the hospitalization cost in patients with AECOP...Background The socio-economic burden of acute exacerbation of chronic obstructive pulmonary disease （AECOPD） in Beijing is not fully understood. The study investigated the hospitalization cost in patients with AECOPD and the associated factors. Methods A multi-center, retrospective study was conducted in the four hospitals in Beijing including two level III hospitals and two level II hospitals. Patients with AECOPD admitted to the hospitals between January and December in 2006 were enrolled. The hospitalization cost and its relationship with disease severity and treatment were analyzed. Results Totally 439 patients were enrolled with 294 men （67.0%） and a mean age 73.4 years. The mean hospital stay was 20.7 days. A total of 204 patients （46.5%） had respiratory failure, 153 （34.9%） with cor pulmonale, 123 （28.0%） with coronary artery disease, 231 （52.6%） with hypertension, 70 （15.9%） with cerebrovascular disease and 32 （7.3%） with renal failure. The percentage of drug cost to total cost was the highest （71.2%）, followed by laboratory cost （16.7%）, therapy cost （9.7%）, oxygen cost （7.3%）, radiology cost （4.5%）, examination cost （4.5%）, bed cost （4.1%）. Correlation analysis showed that cost was positively correlated with age, hospitalization days, co-morbidities such as respiratory failure and cor pulmonale, hypertension. Three hundred and twenty-one patients were further analyzed. The hospitalization cost increased in patients with non-invasive ventilation （P〈0.01）, invasive mechanical ventilation （P〈0.01）, ICU stay （P〈0.01）, antibiotics （P〈0.05）, systemic steroids （P〈0.01）, and poor prognosis （P〈0.05）. Correlation analysis showed that the hospitalization cost was negatively correlated with percentage forced expiratory volume in 1 second （FEV1%） （r=-0.149, P〈0.05）, pH （r=-0.258, P〈0.01）, and PaO2 （r=-0.131, P〈0.05）, positively correlated with PaCO2 （r=0.319, P〈0.01）, non-invasive positive pres展开更多
Hepatitis B virus(HBV) associated acute-on-chronic liver failure(ACLF) is an increasingly recognized fatal liver disease encompassing a severe acute exacerbation of liver function in patients with chronic hepatitis B(...Hepatitis B virus(HBV) associated acute-on-chronic liver failure(ACLF) is an increasingly recognized fatal liver disease encompassing a severe acute exacerbation of liver function in patients with chronic hepatitis B(CHB). Despite the introduction of an artificial liver support system and antiviral therapy, the short-term prognosis of HBV-ACLF is still extremely poor unless emergency liver transplantation is performed. In such a situation, stopping or slowing the progression of CHB to ACLF at an early stage is the most effective way of reducing the morbidity and mortality of HBV-ACLF. It is well-known that the occurrence and progression of HBV-ACLF is associated with many factors, and the outcomes of HBV-ACLF patients can be significantly improved if timely and appropriate interventions are provided. In this review, we highlight recent developments in early warning and clinical outcome prediction in patients with HBV-ACLF and provide an outlook for future research in this field.展开更多
AIM： TO define the potential role of programmed death-i/programmed death-ligand （PD-1/PD-L） pathway in different hepatitis B virus （HBV） infection disease status; we examined the expression of PD-1 on antigen spe...AIM： TO define the potential role of programmed death-i/programmed death-ligand （PD-1/PD-L） pathway in different hepatitis B virus （HBV） infection disease status; we examined the expression of PD-1 on antigen specific CD8＋T cells in peripheral blood of patients with chronic hepatitis B （CriB） and acute exacerbation of hepatitis B （AEHB） infection. METHODS： The PD-1 level on CD8＋ T lymphocytes and the number of HBV specific CD8＋ T lymphocytes in patients and healthy controls （HCs） were analyzed by staining with pentameric peptide-human leukocyte antigen2 （HLA2） complexes combined with flow cytometry. Real-time quantitative polymerase chain reaction （PCR） was used to measure the serum HBV- DNA levels. RESULTS： The level of PD-1 expression on total CD8＋ T cells in CHB patients （13.86% ± 3.38%） was significantly higher than that in AEHB patients （6.80%± 2.19%, P 〈 0.01） and healthy individuals （4.63% ± 1.23%, P 〈 0.01）. Compared to AEHB patients （0.81% ± 0.73%）, lower frequency of HBV-specific CD8＋ T cells was detected in chronic hepatitis B patients （0.37% ± 0.43%, P 〈 0.05）. There was an inverse correlation between the strength of HBV-specific CD8＋ T-cell response and the level of PD-1 expression. Besides, there was a significant positive correlation between HBV viral load and the percentage of PD-1 expression on CD8＋ T cells in CriB and AEHB subjects （R = 0.541, P 〈 0.01）. However, PD-1 expression was not associated with disease flare-ups as indicated by alanine aminotransferase （ALT） levels （R = 0.066, P 〉 0.05）. CONCLUSION： Our results confirm previous reports that HBV specific CD8＋T-cell response in the peripheral blood is more intense in patients with AEHB than in chronic hepatitis B wlth persistent viral infection. Moreover, there is a negative correlation between the level of PD-1 and the intensity of virus specific CD8＋ T cell response.展开更多
AIM: Hepatitis B virus (HBV) re-activation often occurs spontaneously or after withdrawal of immunosuppressive therapy in patients with chronic hepatitis B. Severe exacerbation, sometimes developing into fulminant hep...AIM: Hepatitis B virus (HBV) re-activation often occurs spontaneously or after withdrawal of immunosuppressive therapy in patients with chronic hepatitis B. Severe exacerbation, sometimes developing into fulminant hepatic failure, is at high risk of mortality. The efficacy of corticosteroid therapy in 'clinically severe' exacerbation of chronic hepatitis B has not been well demonstrated. In this study we evaluated the efficacy of early introduction of high-dose corticosteroid therapy in patients with life-threatening severe exacerbation of chronic hepatitis B. METHODS: Twenty-two patients, 14 men and 8 women, were defined as 'severe' exacerbation of chronic hepatitis B using uniform criteria and enrolled in this study. Eleven patients were treated with corticosteroids at 60 mg or more daily with or without anti-viral drugs within 10 d after the diagnosis of severe disease ('early high-dose' group) and 11 patients were either treated more than 10 d or untreated with corticosteroids ('non-early high-dose' group). RESULTS: Mean age, male-to-female ratio, mean prothrombin time (FT) activity, alanine transaminase (ALT) level, total bilirubin level, positivity of HBeAg, mean IgM-HBc titer, and mean HBV DNA polymerase activity did not differ between the two groups. Ten of 11 patients of the 'early high-dose' group survived, while only 2 of 11 patients of the 'non-early high-dose' group survived (P<0.001). During the first 2 wk after the introduction of corticosteroids, improvements in PT activities and total bilirubin levels were observed in the 'early high-dose' group. Both ALT levels and HBV DNA polymerase levels fell in both groups. CONCLUSION: The introduction of high-dose corticosteroid can reverse deterioration in patients with 'clinically life-threatening' severe exacerbation of chronic hepatitis B , when used in the early stage of illness.展开更多
BACKGROUND Acute exacerbation in patients with chronic hepatitis B virus(HBV) infection results in different severities of liver injury. The risk factors related to progression to hepatic decompensation(HD) and acute-...BACKGROUND Acute exacerbation in patients with chronic hepatitis B virus(HBV) infection results in different severities of liver injury. The risk factors related to progression to hepatic decompensation(HD) and acute-on-chronic liver failure(ACLF) in patients with severe acute exacerbation(SAE) of chronic HBV infection remain unknown.AIM To identify risk factors related to progression to HD and ACLF in compensated patients with SAE of chronic HBV infection.METHODS The baseline characteristics of 164 patients with SAE of chronic HBV infection were retrospectively reviewed. Independent risk factors associated with progression to HD and ACLF were identified. The predictive values of our previously established prediction model in patients with acute exacerbation(AE model) and the model for end-stage liver disease(MELD) score in predicting the development of ACLF were evaluated.RESULTS Among 164 patients with SAE, 83(50.6%) had compensated liver cirrhosis(LC),43 had progression to HD without ACLF, and 29 had progression to ACLF within 28 d after admission. Independent risk factors associated with progression to HD were LC and low alanine aminotransferase. Independent risk factors for progression to ACLF were LC, high MELD score, high aspartate aminotransferase(AST) levels, and low prothrombin activity(PTA). The area under the receiver operating characteristic of the AE model [0.844, 95%confidence interval(CI): 0.779-0.896] was significantly higher than that of MELD score(0.690, 95%CI: 0.613-0.760, P < 0.05) in predicting the development of ACLF.CONCLUSION In patients with SAE of chronic HBV infection, LC is an independent risk factor for progression to both HD and ACLF. High MELD score, high AST, and low PTA are associated with progression to ACLF. The AE model is a better predictor of ACLF development in patients with SAE than MELD score.展开更多
目的：对学龄期儿童支气管哮喘（哮喘）中重度急性发作病例的临床特征和治疗转归进行总结分析，为哮喘急性发作的管理提供实践依据。方法收集2005年1月至2013年12月北京儿童医院全部学龄期（≥6岁）哮喘急性发作住院病例214例，分析其...目的：对学龄期儿童支气管哮喘（哮喘）中重度急性发作病例的临床特征和治疗转归进行总结分析，为哮喘急性发作的管理提供实践依据。方法收集2005年1月至2013年12月北京儿童医院全部学龄期（≥6岁）哮喘急性发作住院病例214例，分析其临床特点，将全部病例分为哮喘并肺炎组（ A 组，88例）、哮喘组（B 组，126例），比较2组间差异。结果入组病例年龄中位数9（6~18）岁，男女比例1.5：1.0。中度急性发作78.0％（167/214例），重度22.0％（47/214例）；需机械通气的危重病例7.0％（15/214例）。与 B 组相比，A 组病例全身激素使用比例高（53.4％比38.9％，χ2＝4.416，P ＝0.036）、危重症病例比例高（12.5％比3.3％，χ2＝5.476，P ＝0.019）、住院时间长（9.0 d 比8.0 d，Z ＝-3.063，P ＝0.002）、住院费用高（1.0万元比0.9万元，Z ＝-2.058，P ＝0.000）；喘鸣音持续天数与氨茶碱使用与否无关（5.7 d 比5.9 d，t ＝-0.233，P ＝0.817）。24例在喘息病程中行支气管灌洗治疗，22例（91.7％）灌洗后3 d 内喘鸣音消失；气管镜下有分泌物壅塞的病例，吸入变应原致敏种类数明显多于无该征象者（3.3±1.4比2.2±1.2，t ＝2.190，P ＝0.036）。结论并发肺炎的哮喘急性发作可能更需要早期足量应用全身激素抗炎治疗。致敏变应原的暴露可能使呼吸道分泌物增多，气管镜灌洗有益于改善因分泌物增多造成的呼吸道梗阻。氨茶碱在哮喘发作中的应用需进一步研究论证。展开更多
文摘Background Bacteria-induced respiratory infection has been long considered to be the major cause of acute exacerbation of chronic obstructive pulmonary disease （AECOPD）.Therefore,a clear picture about the distribution and drug-resistance of pathogenic bacteria in the lower airways should be helpful for treatment of the disease.So far,data on this topic among Chinese are lacking.Methods A surveillance study was performed in consecutive patients with AECOPD at five areas in China between October 2006 and April 2008.The sputum from these patients was cultured and isolated for bacteria.Agar dilution method was used to determine the minimal inhibitory concentrations （MICs） of levofloxacin and other 15 antibiotics against these strains.Results Three hundred and fifty-nine pathogenic bacterial strains were isolated among 884 patients with AECOPD.The predominant bacteria were Pseudomonas aeruginosa （21.7%）,Klebsiella pneumoniae （12.3%）,Haemophilus influenzae （14.2%） and Streptococcus pneumoniae （11.7%）,followed by Haemophilus parainfluenzae （9.5%）,Acinetobacter baumannii （7.8%）,Moraxella catarrhalis （6.4%） and Escherichia coli （3.6%）.The majority of bacterial pathogens isolated in this study were susceptible to fluoroquinolones,ceftazidime,cefepime and imipenem.Conclusions Gram-negative bacilli are the leading pathogens in patients with AECOPD in China.Haemophilus parainfluenzae may be one of the most important pathogens in AECOPD.This study provides evidence for local surveillance of AECOPD pathogens and appropriate choice of antimicrobials in China.
文摘Background The socio-economic burden of acute exacerbation of chronic obstructive pulmonary disease （AECOPD） in Beijing is not fully understood. The study investigated the hospitalization cost in patients with AECOPD and the associated factors. Methods A multi-center, retrospective study was conducted in the four hospitals in Beijing including two level III hospitals and two level II hospitals. Patients with AECOPD admitted to the hospitals between January and December in 2006 were enrolled. The hospitalization cost and its relationship with disease severity and treatment were analyzed. Results Totally 439 patients were enrolled with 294 men （67.0%） and a mean age 73.4 years. The mean hospital stay was 20.7 days. A total of 204 patients （46.5%） had respiratory failure, 153 （34.9%） with cor pulmonale, 123 （28.0%） with coronary artery disease, 231 （52.6%） with hypertension, 70 （15.9%） with cerebrovascular disease and 32 （7.3%） with renal failure. The percentage of drug cost to total cost was the highest （71.2%）, followed by laboratory cost （16.7%）, therapy cost （9.7%）, oxygen cost （7.3%）, radiology cost （4.5%）, examination cost （4.5%）, bed cost （4.1%）. Correlation analysis showed that cost was positively correlated with age, hospitalization days, co-morbidities such as respiratory failure and cor pulmonale, hypertension. Three hundred and twenty-one patients were further analyzed. The hospitalization cost increased in patients with non-invasive ventilation （P〈0.01）, invasive mechanical ventilation （P〈0.01）, ICU stay （P〈0.01）, antibiotics （P〈0.05）, systemic steroids （P〈0.01）, and poor prognosis （P〈0.05）. Correlation analysis showed that the hospitalization cost was negatively correlated with percentage forced expiratory volume in 1 second （FEV1%） （r=-0.149, P〈0.05）, pH （r=-0.258, P〈0.01）, and PaO2 （r=-0.131, P〈0.05）, positively correlated with PaCO2 （r=0.319, P〈0.01）, non-invasive positive pres
基金Supported by National Natural Science Foundation of China,No.81300319Science and Technology Support Program of Sichuan Province,China,No.2015SZ0049
文摘Hepatitis B virus(HBV) associated acute-on-chronic liver failure(ACLF) is an increasingly recognized fatal liver disease encompassing a severe acute exacerbation of liver function in patients with chronic hepatitis B(CHB). Despite the introduction of an artificial liver support system and antiviral therapy, the short-term prognosis of HBV-ACLF is still extremely poor unless emergency liver transplantation is performed. In such a situation, stopping or slowing the progression of CHB to ACLF at an early stage is the most effective way of reducing the morbidity and mortality of HBV-ACLF. It is well-known that the occurrence and progression of HBV-ACLF is associated with many factors, and the outcomes of HBV-ACLF patients can be significantly improved if timely and appropriate interventions are provided. In this review, we highlight recent developments in early warning and clinical outcome prediction in patients with HBV-ACLF and provide an outlook for future research in this field.
文摘AIM： TO define the potential role of programmed death-i/programmed death-ligand （PD-1/PD-L） pathway in different hepatitis B virus （HBV） infection disease status; we examined the expression of PD-1 on antigen specific CD8＋T cells in peripheral blood of patients with chronic hepatitis B （CriB） and acute exacerbation of hepatitis B （AEHB） infection. METHODS： The PD-1 level on CD8＋ T lymphocytes and the number of HBV specific CD8＋ T lymphocytes in patients and healthy controls （HCs） were analyzed by staining with pentameric peptide-human leukocyte antigen2 （HLA2） complexes combined with flow cytometry. Real-time quantitative polymerase chain reaction （PCR） was used to measure the serum HBV- DNA levels. RESULTS： The level of PD-1 expression on total CD8＋ T cells in CHB patients （13.86% ± 3.38%） was significantly higher than that in AEHB patients （6.80%± 2.19%, P 〈 0.01） and healthy individuals （4.63% ± 1.23%, P 〈 0.01）. Compared to AEHB patients （0.81% ± 0.73%）, lower frequency of HBV-specific CD8＋ T cells was detected in chronic hepatitis B patients （0.37% ± 0.43%, P 〈 0.05）. There was an inverse correlation between the strength of HBV-specific CD8＋ T-cell response and the level of PD-1 expression. Besides, there was a significant positive correlation between HBV viral load and the percentage of PD-1 expression on CD8＋ T cells in CriB and AEHB subjects （R = 0.541, P 〈 0.01）. However, PD-1 expression was not associated with disease flare-ups as indicated by alanine aminotransferase （ALT） levels （R = 0.066, P 〉 0.05）. CONCLUSION： Our results confirm previous reports that HBV specific CD8＋T-cell response in the peripheral blood is more intense in patients with AEHB than in chronic hepatitis B wlth persistent viral infection. Moreover, there is a negative correlation between the level of PD-1 and the intensity of virus specific CD8＋ T cell response.
文摘AIM: Hepatitis B virus (HBV) re-activation often occurs spontaneously or after withdrawal of immunosuppressive therapy in patients with chronic hepatitis B. Severe exacerbation, sometimes developing into fulminant hepatic failure, is at high risk of mortality. The efficacy of corticosteroid therapy in 'clinically severe' exacerbation of chronic hepatitis B has not been well demonstrated. In this study we evaluated the efficacy of early introduction of high-dose corticosteroid therapy in patients with life-threatening severe exacerbation of chronic hepatitis B. METHODS: Twenty-two patients, 14 men and 8 women, were defined as 'severe' exacerbation of chronic hepatitis B using uniform criteria and enrolled in this study. Eleven patients were treated with corticosteroids at 60 mg or more daily with or without anti-viral drugs within 10 d after the diagnosis of severe disease ('early high-dose' group) and 11 patients were either treated more than 10 d or untreated with corticosteroids ('non-early high-dose' group). RESULTS: Mean age, male-to-female ratio, mean prothrombin time (FT) activity, alanine transaminase (ALT) level, total bilirubin level, positivity of HBeAg, mean IgM-HBc titer, and mean HBV DNA polymerase activity did not differ between the two groups. Ten of 11 patients of the 'early high-dose' group survived, while only 2 of 11 patients of the 'non-early high-dose' group survived (P<0.001). During the first 2 wk after the introduction of corticosteroids, improvements in PT activities and total bilirubin levels were observed in the 'early high-dose' group. Both ALT levels and HBV DNA polymerase levels fell in both groups. CONCLUSION: The introduction of high-dose corticosteroid can reverse deterioration in patients with 'clinically life-threatening' severe exacerbation of chronic hepatitis B , when used in the early stage of illness.
基金Supported by the National Natural Science Foundation of China,No.81460124 and No.81860114
文摘BACKGROUND Acute exacerbation in patients with chronic hepatitis B virus(HBV) infection results in different severities of liver injury. The risk factors related to progression to hepatic decompensation(HD) and acute-on-chronic liver failure(ACLF) in patients with severe acute exacerbation(SAE) of chronic HBV infection remain unknown.AIM To identify risk factors related to progression to HD and ACLF in compensated patients with SAE of chronic HBV infection.METHODS The baseline characteristics of 164 patients with SAE of chronic HBV infection were retrospectively reviewed. Independent risk factors associated with progression to HD and ACLF were identified. The predictive values of our previously established prediction model in patients with acute exacerbation(AE model) and the model for end-stage liver disease(MELD) score in predicting the development of ACLF were evaluated.RESULTS Among 164 patients with SAE, 83(50.6%) had compensated liver cirrhosis(LC),43 had progression to HD without ACLF, and 29 had progression to ACLF within 28 d after admission. Independent risk factors associated with progression to HD were LC and low alanine aminotransferase. Independent risk factors for progression to ACLF were LC, high MELD score, high aspartate aminotransferase(AST) levels, and low prothrombin activity(PTA). The area under the receiver operating characteristic of the AE model [0.844, 95%confidence interval(CI): 0.779-0.896] was significantly higher than that of MELD score(0.690, 95%CI: 0.613-0.760, P < 0.05) in predicting the development of ACLF.CONCLUSION In patients with SAE of chronic HBV infection, LC is an independent risk factor for progression to both HD and ACLF. High MELD score, high AST, and low PTA are associated with progression to ACLF. The AE model is a better predictor of ACLF development in patients with SAE than MELD score.
文摘目的：对学龄期儿童支气管哮喘（哮喘）中重度急性发作病例的临床特征和治疗转归进行总结分析，为哮喘急性发作的管理提供实践依据。方法收集2005年1月至2013年12月北京儿童医院全部学龄期（≥6岁）哮喘急性发作住院病例214例，分析其临床特点，将全部病例分为哮喘并肺炎组（ A 组，88例）、哮喘组（B 组，126例），比较2组间差异。结果入组病例年龄中位数9（6~18）岁，男女比例1.5：1.0。中度急性发作78.0％（167/214例），重度22.0％（47/214例）；需机械通气的危重病例7.0％（15/214例）。与 B 组相比，A 组病例全身激素使用比例高（53.4％比38.9％，χ2＝4.416，P ＝0.036）、危重症病例比例高（12.5％比3.3％，χ2＝5.476，P ＝0.019）、住院时间长（9.0 d 比8.0 d，Z ＝-3.063，P ＝0.002）、住院费用高（1.0万元比0.9万元，Z ＝-2.058，P ＝0.000）；喘鸣音持续天数与氨茶碱使用与否无关（5.7 d 比5.9 d，t ＝-0.233，P ＝0.817）。24例在喘息病程中行支气管灌洗治疗，22例（91.7％）灌洗后3 d 内喘鸣音消失；气管镜下有分泌物壅塞的病例，吸入变应原致敏种类数明显多于无该征象者（3.3±1.4比2.2±1.2，t ＝2.190，P ＝0.036）。结论并发肺炎的哮喘急性发作可能更需要早期足量应用全身激素抗炎治疗。致敏变应原的暴露可能使呼吸道分泌物增多，气管镜灌洗有益于改善因分泌物增多造成的呼吸道梗阻。氨茶碱在哮喘发作中的应用需进一步研究论证。
